🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to health experts.

A Global Challenge

The sexually transmitted infection are increasing around the world, with figures suggesting in excess of 82 million new cases per year. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the reality of rising global incidence, escalating drug resistance and the highly restricted therapeutic options currently available.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Approval

One new antibiotic, also known as Nuzolvence, was authorized by the US FDA in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists believe that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This approval represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Data and Global Access

As per findings published in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The trial involved over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Doctors directly involved have shared optimism. Access to a one-pill regimen of this kind is hailed as a "critical tool" for managing the epidemic. This is viewed as vital to reduce the burden of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.